Pancreatic cancer
Conditions
Interventions
experimental group:gemcitabine plus nab-paclitaxel, paricalcitol and PD-1 antibody
Sponsors
Sun Yat-Sen Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Volunteer to participate and sign written informed consent; 2. Age: 18-72 years old; 3. Pancreatic ductal carcinoma was diagnosed by histology or cytology; 4. MDT team of cancer prevention and treatment center of Sun Yat-Sen University discussed patients with locally advanced pancreatic cancer . 5. The expected survival time was more than 3 months; 6. Be able to take medicine orally; 7. Karnofsky physical fitness score (KPS) >= 70; 8. Proper organ function (within 7 days), as follows: a) AST and ALT = 90g/L, NE>=1.5*10^9/L, PLT >= 90*10^9/L; c) Creatinine clearance rate >= 60 ml / min (based on serum creatinine). 9. Willing and able to follow test visits, test plans, laboratory inspections and other test procedures.
Exclusion criteria
Exclusion criteria: 1. Have received the following treatment in the past: a) Any previous chemotherapy before; b) Any previous radiotherapy or immunotherapy; c) Any investigational drug has been or is being received in the past 30 days; d) Previous surgery within 3 weeks (including ablation, exploration). 2. Previous or present combined with other malignant tumors (except for skin basal cell carcinoma and cervical carcinoma in situ); 3. Other serious diseases or physical conditions, including: a) Patients with severe heart disease history include: congestive heart failure, high risk uncontrollable arrhythmia and hypertension, angina pectoris requiring drug treatment, and history of severe myocardial infarction; b) Active infection or active infectious disease; c) Known gastrointestinal disorders at the time of enrollment, including dyspepsia, diarrhea, etc.; d) Habitual nausea, vomiting or diarrhea; e) Poorly controlled diabetes. 4. With serious complications such as active gastrointestinal bleeding, perforation, jaundice, intestinal obstruction, etc.; 5. Mental disorders, which may affect the recognition of informed consent and the implementation of the experimental scheme; 6. Other severe acute or chronic physical discomfort and abnormal laboratory examination may increase the expected risk of the trial, affect the progress of treatment, or interfere with the results of the study. The investigator shall judge whether the subject is eligible for the trial; 7. Pregnant and lactating women, or subjects who are fertile but refuse to use appropriate contraceptive measures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;AEs;SR; | — |
Countries
China
Contacts
Public ContactLi shengping
Sun Yat-Sen Cancer Center
Outcome results
None listed